(secondQuint)CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer.

 PRIMARY OBJECTIVES: I.

 To evaluate the safety and anti-cancer activities in patients with relapsed or refractory small cell lung cancer (SCLC) who have failed 1 or 2 lines of chemotherapy.

 OUTLINE: Patients receive CPI-613 intravenously (IV) over 2 hours on days 1 and 4 of weeks 1-3.

 Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

 After completion of study treatment, patients are followed up every 2 months.

.

 CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer@highlight

This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer.

 CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.

